Quantum biochemistry description of PI3Kα enzyme bound to selective inhibitors

被引:1
|
作者
de Sousa, Francisca Joseli Freitas [1 ]
Azevedo, Francisca Fernanda Nunes [1 ]
de Oliveira, Francisco Lucas Santos [2 ]
Carletti, Jaqueline Vieira [3 ]
Freire, Valder Nogueira [4 ]
Zanatta, Geancarlo [1 ,2 ]
机构
[1] Univ Fed Ceara, Dept Biochem & Mol Biol, Fortaleza, Brazil
[2] Univ Fed Rio Grande do Sul, Dept Biophys, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, Brazil
[4] Univ Fed Ceara, Dept Phys, Fortaleza, Brazil
来源
关键词
Alpelisib; GDC-0326; PI3K alpha-inhibitors; phosphoinositide-3-kinase; molecular fragmentation with conjugated caps; quantum calculation; POPULATION ANALYSIS; INFORMATION-THEORY; ISOFORM; IDENTIFICATION; MECHANICS; BINDING; DESIGN; NVP-BYL719; MOLECULES; DISCOVERY;
D O I
10.1080/07391102.2023.2251063
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PI3K class I is composed of four PI3K isoforms that serve as regulatory enzymes governing cellular metabolism, proliferation, and survival. The hyperactivation of PI3K alpha is observed in various types of cancer and is linked to poor prognosis. Unfortunately, the development inhibitors selectively targeting one of the isoforms remains challenging, with only few agents in clinical use. The main difficulty arises from the high conservation among residues at the ATP-binding pocket across isoforms, which also serves as target pocket for inhibitors. In this work, molecular dynamics and quantum calculations were performed to investigate the molecular features guiding the binding of selective inhibitors, alpelisib and GDC-0326, into the ATP-binding pocket of PI3K alpha. While molecular dynamics allowed crystallographic coordinates to relax, the interaction eergy between each amino acid residues and inhibitors was obtained by combining the Molecular Fractionation with Conjugated Caps scheme with Density Functional Theory calculations. In addition, the atomic charge of ligands in the bound and unbound (free) was calculated. Results indicated that the most relevant residues for the binding of alpelisib are Ile932, Glu859, Val851, Val850, Tyr836, Met922, Ile800, and Ile848, while the most important residues for the binding of GDC-0326 are Ile848, Ile800, Ile932, Gln859, Glu849, and Met922. In addition, residues Trp780, Ile800, Tyr836, Ile848, Gln859 Val850, Val851, Ile932 and Met922 are common hotspots for both inhibitors. Overall, the results from this work contribute to improving the understanding of the molecular mechanisms controlling selectivity and highlight important interactions to be considered during the rational design of new agents.
引用
收藏
页码:9283 / 9293
页数:11
相关论文
共 50 条
  • [21] Isoform-Selective PI3K Inhibitors for Various Diseases
    Bheemanaboina, Rammohan R. Y.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (12) : 1074 - 1092
  • [22] Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3Kγ
    Sha, Shao
    Han, Hong-Wei
    Gao, Fei
    Liu, Tian-Bao
    Li, Zhen
    Xu, Chi
    Zhong, Wei-Qing
    Zhu, Hai-Liang
    MEDCHEMCOMM, 2015, 6 (11) : 2029 - 2035
  • [23] Synthesis and SAR study of potent and selective PI3Kδ inhibitors
    Bui, Minna
    Hao, Xiaolin
    Shin, Youngsook
    Cardozo, Mario
    He, Xiao
    Henne, Kirk
    Suchomel, Julia
    McCarter, John
    Mcgee, Lawrence R.
    Miguel, Tisha San
    Medina, Julio C.
    Mohn, Deanna
    Tran, Thuy
    Wannberg, Sharon
    Wong, Jamie
    Wong, Simon
    Zalameda, Leeanne
    Metz, Daniela
    Cushing, Timothy D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (05) : 1104 - 1109
  • [24] Discovery of novel class of alpha selective PI3K inhibitors
    Garland, Keira
    Hanan, Emily
    Staben, Steven
    Braun, Marie-Gabrielle
    Edgar, Kyle
    Endres, Nick
    Friedman, Lori
    Nguyen, Amanda
    Pang, Jodie
    Purkey, Hans
    Salphati, Laurent
    Schmidt, Stephen
    Song, Kyung
    Ultsch, Mark
    Jaochico, Allan
    Chan, Connie
    Eigenbrot, Charles
    MacLeod, Calum
    Jackson, Philip
    Narukulla, Raman
    Knight, Jamie
    Yeap, Kuen
    Messick, Kristen
    Valle, Nicole
    Heald, Robert
    Nannini, Michelle
    Hamilton, Pat
    Clausen, Saundra
    Young, Amy
    Sampath, Deepak
    Hong, Rebecca
    Lee, Man-Ling
    Blench, Toby
    Elliott, Richard
    Lu, Aijun
    Gu, Xiao-Hu
    Xin, Jianfeng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [25] Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors
    Barlaam, Bernard
    Cosulich, Sabina
    Fitzek, Martina
    Germain, Herve
    Green, Stephen
    Hanson, Lyndsey L.
    Harris, Craig S.
    Hancox, Urs
    Hudson, Kevin
    Lambert-van der Brempt, Christine
    Lamorlette, Maryannick
    Magnien, Francoise
    Ouvry, Gilles
    Page, Ken
    Ruston, Linette
    Ward, Lara
    Delouvrie, Benedicte
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (13) : 3030 - 3035
  • [26] Selective PI3Kδ Inhibitors as Anti-NASH Agents
    Vakkalanka, Swaroop
    Muthuppalaniappan, Meyyappan
    Babu, G.
    Varanasi, Kanthikiran
    Routhu, Kasiviswanath
    Nyayapathy, Seeta
    Veeraraghavan, Sridhar
    Viswanadha, Srikant
    Nagaratham, Dhanapalan
    DIABETES, 2012, 61 : A84 - A84
  • [27] Highly Selective Inhibitors Of Pi3kγ For The Oral Treatment Of COPD
    Karabelas, K.
    Arlbrandt, S.
    Bold, P.
    Butcher, A.
    Carlsson, J. F.
    Cygan, P.
    Ehnebom, J.
    Goodyear, C.
    MacLellan, L.
    Nordberg, M.
    Lindmark, H.
    Mogemark, M.
    Pehrson, R.
    Perry, M.
    Blomqvist, S. R.
    Stern, A.
    Thomas, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [28] Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors
    Sun, Jiajia
    Feng, Yifan
    Huang, Yuan
    Zhang, San-Qi
    Xin, Minhang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (19)
  • [29] Imidazopyridazine Inhibitors of PI3Kβ
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1012 - 1013
  • [30] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740